Spots Global Cancer Trial Database for Clinical Study of AL2846 Capsule in the Treatment of Differentiated Thyroid Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Clinical Study of AL2846 Capsule in the Treatment of Differentiated Thyroid Cancer
Official Title: Phase Ib Clinical Trial to Evaluate the Efficacy and Safety of AL2846 Capsule in Iodine-resistant Differentiated Thyroid Cancer With Previous TKI Treatment Failure
Study ID: NCT05745363
Conditions
Interventions
Study Description
Brief Summary: This is a Phase Ib clinical trial to evaluate the efficacy and safety of AL2846 capsule in iodine-refractory differentiated thyroid cancer that has failed previous TKI treatment. The trial is planned to enroll 20 subjects. The trial is a single-arm, multi-center, open label clinical study. Objective response rate (ORR) is the primary endpoint.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Affiliated Hospital Of Guilin Medical University, Guilin, Guangxi, China
Hunan Cancer Hospital, Changsha, Hunan, China
Jiangxi Cancer Hospital, Nanchang, Jiangxi, China
Yunnan Cancer Hospital, Kunming, Yunnan, China
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
